1 / 35

Transatlantic Conference Brussels, November 12, 2013 “Time to Rethink our Policy on Drugs -

Transatlantic Conference Brussels, November 12, 2013 “Time to Rethink our Policy on Drugs - Experiences from Europe and the Americas” Pave l Bem, MD. National Drug Commission, Czech Republic Global Commission on Drug Policy. „ Opportunities and risks stay so close together…“.

sagira
Télécharger la présentation

Transatlantic Conference Brussels, November 12, 2013 “Time to Rethink our Policy on Drugs -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Transatlantic Conference Brussels, November 12, 2013 “Time to Rethink our Policy on Drugs - Experiences from Europe and the Americas” Pavel Bem, MD. National Drug Commission, Czech Republic Global Commission on Drug Policy

  2. „Opportunities and risks stay so close together…“

  3. 50 Years of World’s Experience of Combating Illicit Drugs • International cooperation in supply reduction • Crop eradication • Policies based on balanced approach between repression and prevention • Role of primary prevention/health education • Treatment and rehabilitation • Focus at urban policies

  4. 50 years of wishful thinking

  5. Negative Results:Supply reduction failed • Supply of illicit opioids has increased 400% in last 30 years • 75% decrease of heroin black market price • 900% increase in heroin purity • US budget increase in war on drugs: 600% (United Nations Office on Drug and Crime, 2010) No effect on supply reduction side

  6. Negative Results:”Balanced” drug policies failed • Drug policy “driven” HIV epidemics, mortality • Policy “driven” HCV epidemics, morbidity • Missing balance in total expenditures: “supply vs. demand” 80% vs. 20% • Failure in assessment of evidence based approach 20% vs. 80% • Failure of national as well as supranational organizations in effective response Unintended negative consequences

  7. Mustang: Ghar, Ghiling Gompa, 9-10th cent. “Unintended negative consequences”: Overall cost is to high…

  8. BUT… We act only on the “surface” of the problem…

  9. Positive Results:Demand and harm reduction works • Reducing HIV prevalence among PDU’s • Reducing HCV prevalence among PDU’s • Reducing hidden population of PDU’s • Reducing mortality among PDU’s • Reducing morbidity among PDU’s • Reducing not only public health risks, but overall social and economic costs

  10. The need for paradigm change • Acceptance of failures • Understanding of best practices • The role of supranational authorities: Active leadership (Latin America + Europe…) l

  11. The need for paradigm change • Prague: case study • Czech experience • Global Commission on Drug Policy

  12. Prague Drug Policy Design • Pragmatic approach • Realistic attitude • Data based design • Balanced policy and measurable outcomes

  13. Prague Drug Policy Design • Balance between public health and safety • Economy driven drug policy • Evidence based interventions • Police does it’s job on drug supply side • Demand and harm reduction services • Measurable outcomes (HIV, HCV, morbidity)

  14. Prague Drug Policy Design • Availability of needles and syringes • Availability of services + outreach • Methadone + Buprenorphine + … • Non-punitive legal framework (possession is not legal offence)

  15. HIV prevalence among IUDs in Europe

  16. Drug Overdoses–EU Countries

  17. Where are the benefits? • Low proportion of hidden population (< 30%) • Low mortality rate • Low prevalence of HIV among PDU’s-IVDU • Manageable morbidity rates • Manageable dynamics • Reduced public health risks • Acceptable economic and social costs 14

  18. BUT…

  19. We behave in simplistic way with no respect to human diversity and human rights (Papua, 2003)

  20. New Penal Code: 1998 Penalizing possession Czech Republic case study

  21. PAD: Impact Analysis Project of the New Drug Legislation Complex Cost and Benefit Analysis (5 major studies and 20 sub studies): 1. Secondary analysis of school surveys 2. Prevalence study of problem drug use in the CR 3. Economic and social cost of illegal drug use in the CR 4. Qualitative study among illicit drug users 5. Cost and benefit analysis of the implementation of penalization of possession of illicit drugs for personal use

  22. Research Methodology • Combination of quantitative and qualitative methods • Measuring the direct as well as indirect costs • Interdisciplinary research team • Supervised by Florida State University, School of Criminal Justice • Granted by the National Drug Commission

  23. Main Hypothesis • 1. Availability of Illicit Drugs Will Decrease • 2. Use of Illicit Drugs Will Decrease • 3. Incidence of Illicit Drug Use Will Decrease • 4. Negative Health Indicators Will Not Increase • 5. Social Costs Related to Drug Abuse Will Not Increase After Introduction of a Penalty of Possession for Personal Use

  24. Results • All hypothesis were rejected in 3 years study • No positive impact of the criminalization law at all Lead to Decriminalization Act 2008 • Evidence based additional costs for public budgets

  25. RecommendationsPrague Declaration, 20091.No size fits all2.Realism is the key3.Human rights apply to ill people in particular4.Public health and public safety concerns must not be seen as contradictory5.Evidence based decision only6.Evaluation and monitoring7.Constant and improving mutual information flow

  26. Drug Policies at Crossroad Conclusions: 1. War on drugs has failed:Need for “rebalancing action” in drug policies design

  27. Drug Policies at Crossroad Conclusions: 2. Need for wider implementation of cost effective public health measures:Harm reduction services especially at areas of high risk

  28. Drug Policies at Crossroad Conclusions: 3. Decriminalization of drug possession and drug consumption worldwide

  29. Drug Policies at Crossroad Conclusions: 4. Reallocation of drug budget priorities

  30. The need for paradigm change • Growing awareness internationally (Global Commission on Drug Policy: former presidents, prime ministers, UN officials, intellectuals…) • Vienna high level meeting: CND 2014 (EU Action Plan on Drugs 2013-2016, action #5] • UNGASS 2016

  31. “Wishful thinking” is still prevailing among many politicians, decision makers as well as media

  32. www.globalcommissionondrugs.orgwww.vlada.czwww.cadap.eu www.praguedeclaration.comkThank you for your attention

More Related